三阴性乳腺癌分子分型洞见:改善治疗的患者筛选
三阴性乳腺癌(TNBC)仍是治疗难度最高的乳腺癌亚型,靶向特定分子靶点的疗法鲜少在TNBC患者中实现有临床意义的结局改善,化疗仍是标准治疗。本文综述基于肿瘤细胞组成与分子特征全面分析对TNBC进行分型的最新进展;技术进步使肿瘤特征描述日益深入,若与临床病理特征整合,可能有助于改善风险分层、指导治疗决策与监测,并识别新药开发靶点。
要点
- TNBC较其他主要乳腺癌亚型复发率更高、转移潜能更大、总生存更短。
- 能够指导TNBC治疗决策的生物标志物识别仍是临床未满足的需求。
- 理解耐药驱动机制是设计新治疗策略以预防转移、最终改善生存的关键。
核心结论
- TNBC仍是治疗难度最高的乳腺癌亚型,针对特定分子靶点的疗法鲜少在TNBC患者中实现有临床意义的结局改善,化疗仍是标准治疗。
- 基于肿瘤细胞组成与分子特征全面分析对TNBC进行分型的最新进展,若与临床病理特征整合,可能有助于改善风险分层、指导治疗决策与监测,并识别新药开发靶点。
研究设计与样本
- 本文为综述,旨在回顾基于肿瘤细胞组成与分子特征全面分析对TNBC进行分型的最新工作。
主要发现
- TNBC与其他主要乳腺癌亚型相比复发率更高、转移潜能更大、总生存更短。
- 能够指导TNBC治疗决策的生物标志物识别仍是临床未满足的需求。
- 理解耐药驱动机制是设计新治疗策略以预防转移、最终改善生存的关键。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Triple-negative breast cancer (TNBC) remains the most challenging breast cancer subtype to treat. To date, therapies directed to specific molecular targets have rarely achieved clinically meaningful improvements in outcomes of patients with TNBC, and chemotherapy remains the standard of care. Here, we seek to review the most recent efforts to classify TNBC based on the comprehensive profiling of tumors for cellular composition and molecular features. Technologic advances allow for tumor characterization at ever-increasing depth, generating data that, if integrated with clinical-pathologic features, may help improve risk stratification of patients, guide treatment decisions and surveillance, and help identify new targets for drug development. SIGNIFICANCE: TNBC is characterized by higher rates of relapse, greater metastatic potential, and shorter overall survival compared with other major breast cancer subtypes. The identification of biomarkers that can help guide treatment decisions in TNBC remains a clinically unmet need. Understanding the mechanisms that drive resistance is key to the design of novel therapeutic strategies to help prevent the development of metastatic disease and, ultimately, to improve survival in this patient population.
引用
- Garrido-Castro AC, Lin NU, Polyak K, et al. Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. Cancer Discov. 2019. PMID: 30679171. doi:10.1158/2159-8290.CD-18-1177
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。